Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 5, 2014, Pages 969-980

  Wada, Russ ^a   Erickson, Hans K ^b,c   Lewis Phillips, Gail D ^c   Provenzano, Carmela A ^b   Leipold, Douglas D ^c   Mai, Elaine ^c   Johnson, Holly ^b   Tibbitts, Jay ^c,d  

^a Quantitative Solutions   (United States)

^b IMMUNOGEN INC   (United States)

^c GENENTECH INC   (United States)

^d UCB PHARMA   (Belgium)

Author keywords

Antibody drug conjugate; Pharmacokinetics pharmacodynamics; T DM1; Target cell catabolism; Trastuzumab emtansine

Indexed keywords

TRASTUZUMAB EMTANSINE; MAYTANSINE; MONOCLONAL ANTIBODY; TRITIUM;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG UPTAKE; EC50; FEMALE; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; RADIOACTIVITY; SINGLE DRUG DOSE; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; VOLUME OF DISTRIBUTION; ALGORITHM; ANALOGS AND DERIVATIVES; ANIMAL; AREA UNDER THE CURVE; BIOLOGICAL MODEL; BLOOD; HUMAN; METABOLISM; NEOPLASMS; NUDE MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; CELL LINE, TUMOR; FEMALE; HUMANS; MAYTANSINE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS; TREATMENT OUTCOME; TRITIUM;

EID: 84919710736     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2561-2     Document Type: Article

References (25)

1. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA (2010) Phase I study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704
2. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821
3. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) - positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405
4. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235-244
5. Junttila TT, Li G, Parsons K, Lewis Phillips G, Sliwkowski MX (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356
6. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA (2006) Anti-body-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433
7. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84-92
8. Erickson HK, Lewis-Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, Pinkas J, Tibbitts J (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 11:1133-1142
9. Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, Benjamin DR (2009) The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330:932-938
10. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888-897
11. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124
12. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J (2000) Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40:1399-1418
13. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA (2008) Mechanism-based pharmacokinetic-pharmacodynamic (PK/PD) modeling in translational drug research. Trends Pharmacol Sci 29:186-191
14. Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ (2000) Models of schedule dependent hematological toxicity 2′-deoxy-2′-methylidinecytidine (DMDC). Eur J Clin Pharmacol 56:567-574
15. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T (2008) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267-1274
16. Wang S, Zhou Q, Gallo JM (2009) Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose strategy of gefitinib. Mol Cancer Ther 8:1438-1447
17. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
18. Shen B-Q, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu Y-W, LoRusso PM, Girish S (2012) Catabolic fate and pharmacokinetic characterization of Trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 13:901-910
19. Jumbe NL, Yan X, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J (2010) Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 37:221-242
20. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101
21. Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82:17-20
22. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Molec Biol Cell 15:5268-5282
23. Shah DK, Haddish-Berhan N, Betts A (2012) Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn 39:643-659
24. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA (2006) Anti-body-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker dependent intracellular processing. Cancer Res 66(8):4426-4433
25. Chudasama VL, Stark FS, Harrold JM, Tibbetts J, Girish SR, Gupta M, Frey N, Mager DE (2012) Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 92(4):520-527